Coronavirus: More than 40,000 health-care workers taking part in hydroxychloroquine trial

Must Read

No injuries as fire aboard Suncor’s Terra Nova vessel extinguished

ST. JOHN'S, N.L. — Suncor Energy officials say a fire onboard the Terra Nova Floating Production Storage and Offloading vessel...

One more new case of COVID-19 in the Northern Health region

VICTORIA, B.C. – There is one new case of COVID-19 in the Northern Health region, bringing our...

50 to 60 percent of SD60 students expected to return to class starting June 1

FORT ST. JOHN, B.C. - Many students across the province will be returning to school on Monday, June 1,...

LONDON/BANGKOK — Healthcare workers in Britain and Thailand have started taking part in a trial to determine whether two anti-malarial drugs can prevent COVID-19, including one that U.S. President Donald Trump says he has been taking.

The study, involving more than 40,000 healthcare workers across Europe, Africa, Asia and South America, seeks to determine whether chloroquine and hydroxychloroquine could play a role in the fight against the novel coronavirus.

Demand for hydroxychloroquine surged after Trump touted it in early April. He said this week he was now taking it as a preventive medicine against the virus despite medical warnings about its use.

- Advertisement -

Community Interviews with Moose FM


The lead investigators in Thailand and Britain said their ‘COPCOV’ trial, in the works for several months, would cut through the heated and unhelpful debate.

Story continues below advertisement

“We still do not know whether anything is beneficial in COVID-19,” the University of Oxford’s Professor Nicholas White, the study’s co-principal investigator, told Reuters.

“The only way we can find out if things are beneficial overall is to do large, well-conducted clinical trials,” said White, who is based at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok.

 » READ MORE FROM GLOBAL NEWS

More Articles Like This